1-13 of 13
Pallavi Pillai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time

James Troyer, Bonnie Lu, Kathryn Krause, Melanie Aviles, Sherraine Della-Moretta, Dre'Von Dobson, Kaveh Farrokhi, Zainul S. Hasanali, Ajibike Lapite, Pallavi Pillai, Cristian Taborda, Lynda Villagomez, Phuong T Vo, Ruth Wang'ondu, Jennifer C. Yui, Angela C Weyand, Warren B. Fingrut
Journal: Blood
Blood (2024) 144 (Supplement 1): 5207.
https://doi.org/10.1182/blood-2024-206364
Published: 2024
Journal Articles

Circulating Tumor DNA (ctDNA) Assessment in Pediatric Patients with Newly Diagnosed High-Risk Classic Hodgkin Lymphoma (cHL): Exploratory Analysis from the Phase 2 Keynote-667 Study

Christine Mauz-Koerholz, Luciana Vinti, Gerard Michel, Auke Beishuizen, Franca Fagioli, Lorena Valero-Arrese, Salvatore Buffardi, Michaela Cepelova, Stephen Daw, Antony Ceraulo, Thierry Leblanc, Anne Thorwarth, Charlotte Rigaud, Theresa Jox, Maximilian Dörrbecker, Stefan Gattenlöhner, Marek Bartkuhn, Mackenzie Edmondson, Yuehui Zhao, Haitao Li, Pallavi Pillai, Razvan Cristescu, Carol Peña, Andreas Bräuninger
Journal: Blood
Blood (2024) 144 (Supplement 1): 6196.
https://doi.org/10.1182/blood-2024-200309
Published: 2024
Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Christine Mauz-Koerholz, Luciana Vinti, Stephen Daw, Antony Ceraulo, Gerard Michel, Michaela Cepelova, Lorena Valero-Arrese, Franca Fagioli, Stéphane Ducassou, Salvatore Buffardi, Thierry Leblanc, Bradford S Hoppe, Frank G. Keller, Kara M. Kelly, Lisa Giulino Roth, Judith Landman-Parker, Juan Shen, Pallavi Pillai, Rushdia Yusuf, Auke Beishuizen
Journal: Blood
Blood (2024) 144 (Supplement 1): 3055.
https://doi.org/10.1182/blood-2024-199675
Published: 2024
Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Lisa Giulino Roth, Mario Melgar Toledo, Frank G. Keller, Bradford Hoppe, Christopher J. Forlenza, Sharon M. Castellino, Maitane Andión Catalan, Julie Krystal, Adam Lamble, Flavio Luisi, Fabio Molina Morales, Aarati V. Rao, Stacy Cooper, Oscar Gonzalez Llano, Luis Juarez Villegas, Christine Mauz-Koerholz, Juan Shen, Pallavi Pillai, Rushdia Yusuf, Kara M. Kelly
Journal: Blood
Blood (2024) 144 (Supplement 1): 462.
https://doi.org/10.1182/blood-2024-199263
Published: 2024
Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

Lisa Giulino Roth, Frank Keller, Mario Melgar Toledo, Sharon M. Castellino, Christopher J. Forlenza, Maitane Andión Catalan, Julie Krystal, Adam Lamble, Aarati V. Rao, Fabio Molina Morales, Stacy Cooper, Flavio Luisi, Oscar Gonzalez Llano, Karla Alejandra Lopez, Christine Mauz-Koerholz, Bradford Hoppe, Juan Shen, Pallavi Pillai, Patricia Marinello, Kara M. Kelly
Journal: Blood
Blood (2023) 142 (Supplement 1): 1700.
https://doi.org/10.1182/blood-2023-186719
Published: 2023
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 4440.
https://doi.org/10.1182/blood-2023-182019
Published: 2023
Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1725.
https://doi.org/10.1182/blood-2023-182536
Published: 2023
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1693.
https://doi.org/10.1182/blood-2023-182128
Published: 2023
Journal Articles

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie, John Timmerman, Ramón García-Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel L. Molin, Muhit Ozcan, Omur Gokmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 3082.
https://doi.org/10.1182/blood-2023-182119
Published: 2023
Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Christine Mauz-Koerholz, Auke Beishuizen, Luciana Vinti, Antony Ceraulo, Gerard Michel, Michaela Cepelova, Franca Fagioli, Constantino Sabado Alvarez, Stephane Ducassou, Salvatore Buffardi, Maitane Andión Catalan, Brad Hoppe, Frank Keller, Kara M. Kelly, Lisa Giulino Roth, Judith Landman-Parker, Juan Shen, Pallavi Pillai, Stephen Daw
Journal: Blood
Blood (2023) 142 (Supplement 1): 3063.
https://doi.org/10.1182/blood-2023-187028
Published: 2023
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Akash Nahar, John Timmerman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6540–6542.
https://doi.org/10.1182/blood-2022-166846
Published: 2022
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tsoran-Rosenthal, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Akash Nahar, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 768–770.
https://doi.org/10.1182/blood-2022-166670
Published: 2022
Journal Articles

Outcome of Post Solid Organ Transplant Burkitt Lymphoma (PSOT-BL): A Report from the Pediatric PTLD Collaborative (PPC)

Zeinab Afify, Manuela Orjuela, Christine Moore Smith, Mansi Dalal, James B. Ford, Pallavi Pillai, Joanna Robles, Sonika Reddy, Sarah McCormack, Matt J. Ehrhardt, Tonya Ureda, Holly Edington, Tamara P. Miller, Jeremy Rubinstein, Lianna Marks, Clint C. Mason
Journal: Blood
Blood (2021) 138 (Supplement 1): 2498.
https://doi.org/10.1182/blood-2021-149033
Published: 2021